A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease
- PMID: 17053008
- DOI: 10.1093/eurheartj/ehl334
A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease
Abstract
Aims: The role of aspirin in patients with coronary artery disease (CAD) is well established, yet patients happen to discontinue aspirin according to physician's advice or unsupervised. We thus undertook a systematic review to appraise the hazards inherent to aspirin withdrawal or non-compliance in subjects at risk for or with CAD.
Methods and results: Electronic databases were systematically searched (updated January 2006). Study designs, patient characteristics, and outcomes were abstracted. Pooled estimates for odds ratios (OR) were computed according to random-effect methods. From the 612 screened studies, six were selected (50,279 patients). One study (31,750 patients) focused on adherence to aspirin therapy in the secondary prevention of CAD, two studies (2594) on aspirin discontinuation in acute CAD, two studies (13,706) on adherence to aspirin therapy before or shortly after coronary artery bypass grafting, and another (2229) on aspirin discontinuation among patients undergoing drug-eluting stenting. Overall, aspirin non-adherence/withdrawal was associated with three-fold higher risk of major adverse cardiac events (OR=3.14 [1.75-5.61], P=0.0001). This risk was magnified in patients with intracoronary stents, as discontinuation of antiplatelet treatment was associated with an even higher risk of adverse events (OR=89.78 [29.90-269.60]).
Conclusion: Non-compliance or withdrawal of aspirin treatment has ominous prognostic implication in subjects with or at moderate-to-high risk for CAD. Aspirin discontinuation in such patients should be advocated only when bleeding risk clearly overwhelms that of atherothrombotic events.
Similar articles
-
The hazards of discontinuing acetylsalicylic acid therapy in those at risk of coronary artery disease.Curr Opin Cardiol. 2008 Sep;23(5):487-93. doi: 10.1097/HCO.0b013e32830b5afa. Curr Opin Cardiol. 2008. PMID: 18670261 Review.
-
Antiplatelet effect of aspirin in patients with coronary artery disease.Dan Med J. 2012 Sep;59(9):B4506. Dan Med J. 2012. PMID: 22951204 Review.
-
Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management.Arch Cardiovasc Dis. 2011 May;104(5):306-12. doi: 10.1016/j.acvd.2011.03.091. Epub 2011 May 31. Arch Cardiovasc Dis. 2011. PMID: 21693367
-
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.Thromb Haemost. 2015 Feb;113(2):272-82. doi: 10.1160/TH14-05-0436. Epub 2014 Oct 2. Thromb Haemost. 2015. PMID: 25274620
-
Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.Pharmacol Res. 2013 Aug;74:7-22. doi: 10.1016/j.phrs.2013.04.010. Epub 2013 May 7. Pharmacol Res. 2013. PMID: 23665469 Clinical Trial.
Cited by
-
Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks.BMC Med. 2015 Mar 19;13:55. doi: 10.1186/s12916-015-0285-8. BMC Med. 2015. PMID: 25857826 Free PMC article.
-
Platelet Aggregation Inhibitors and Anticoagulants in Gastroenterological and Visceral Surgical Procedures.Dtsch Arztebl Int. 2022 Dec 9;119(49):851-860. doi: 10.3238/arztebl.m2022.0342. Dtsch Arztebl Int. 2022. PMID: 36345703 Free PMC article. Review.
-
Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.Vasc Health Risk Manag. 2013;9:245-54. doi: 10.2147/VHRM.S44265. Epub 2013 May 16. Vasc Health Risk Manag. 2013. PMID: 23696706 Free PMC article. Review.
-
The Risk of Bleeding and Adverse Events with Clopidogrel in Elective Hip and Knee Arthroplasty Patients.J Clin Med. 2022 Mar 22;11(7):1754. doi: 10.3390/jcm11071754. J Clin Med. 2022. PMID: 35407361 Free PMC article.
-
Update on the management of upper gastrointestinal bleeding.BMJ Med. 2022 Sep 28;1(1):e000202. doi: 10.1136/bmjmed-2022-000202. eCollection 2022. BMJ Med. 2022. PMID: 36936565 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous